MedTrace Logo

Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

NCT06011343 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-08-25

No results posted yet for this study

Summary

Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the time of cure of the disease.

Conditions

  • Cutaneous Leishmaniasis, American

Interventions

DRUG

Oral tofacitinib

Association of tofacitinib and meglumine antimoniate

DRUG

Parenteral meglumine antimoniate

Meglumine antimoniate

Sponsors & Collaborators

  • Instituto Gonçalo Muniz FIOCRUZ BA

    collaborator UNKNOWN

  • Hospital Universitário Professor Edgard Santos

    lead OTHER

Principal Investigators

  • EDGAR CARVALHO, MD, PhD · Federal University of Bahia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-10-01
Completion
2025-07-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011343 on ClinicalTrials.gov